FDA Determines Regulatory Review Period for STRENSIQ Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for STRENSIQ, a human biological product, following a submission to the U.S. Patent and Trademark Office (USPTO) for patent extension.